These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2010-021850-20 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4... 2016-07-06 due-trials
Completed, but no date, and reported results 2017-004018-25 A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positi... bad-data
Completed, but no date, and reported results 2017-004600-22 A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Type 3 Studio clinico rand... bad-data
Completed, but no date Terminated 2017-004777-14 Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis patients Studio sulla sicurezza a lungo termine dell’amifampri... bad-data
Completed, but no date Terminated 2018-000160-28 Long term safety study of amifampridine phosphate in ambulatory patients with Spinal Muscular Atrophy (SMA) type 3 Long term safety study of amifampridine phosphate in ambulatory patients with Spin... bad-data
Completed, but no date, and reported results Terminated 2018-000358-23 A phase 3, multicenter, double-blind, placebo-controlled, randomized, outpatient two-period two-treatment crossover study to evaluate the efficacy and safety of amifampridine phosphate (3,4 diaminopyr... bad-data
Completed, but no date Terminated 2018-002405-64 Long term safety study of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS) Studio sulla sicurezza a lungo termine dell’amifampridina fosfato nei pazienti con Sindromi... bad-data